Ivermectin’s Potential Impact on Covid-19 Mortality
Shared By Peter Boykin – American Political Commentator / Citizen Journalist
Ivermectin’s Potential Impact on Covid-19 Mortality
Ivermectin’s Potential Impact on Covid-19 Mortality
A peer-reviewed study has investigated the potential correlation between widespread use of Ivermectin and a significant reduction in excess Covid-19-related fatalities in Peru.
The background of the study originates from the early stages of the pandemic, when anecdotal reports from medical professionals suggested potential benefits of Ivermectin in aiding patients’ recovery from Covid-19. Originally approved by the FDA in 1986 for addressing parasites and infections, the drug garnered attention due to these initial observations.
The study focused on the period prior to the availability of vaccines, during which Peru granted authorization for the broad use of Ivermectin in Covid-19 treatment. Examination of data from 25 regions within Peru revealed noteworthy findings: states with higher Ivermectin utilization experienced a notable 74% reduction in excess mortality.
A causal relationship was explored, exemplified by events in Peru when Francisco Sagasti assumed office in November 2020. His decision to curtail the widespread distribution of Ivermectin was associated with subsequent developments: there was a substantial 14-fold decrease in excess deaths while the drug was widely accessible, followed by a 13-fold increase in such deaths after its distribution was restricted.
This pattern finds resonance in other regions, such as Uttar Pradesh, India, where widespread distribution of Ivermectin was linked to a remarkable 97% reduction in Covid-19 deaths. Notably, the combined population of Peru and Uttar Pradesh amounts to approximately 262 million.
During the summer of 2021, a period marked by the Biden administration’s concentrated efforts on mass vaccination, the FDA expressed skepticism about Ivermectin through a tweet and an accompanying article. The agency discouraged its use in the context of Covid-19, emphasizing that it is intended for neither humans nor standard livestock.
[Source: Epoch Times]
